Welcome to our dedicated page for INOVIO PHARMACEUTICALS SEC filings (Ticker: INO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on INOVIO PHARMACEUTICALS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into INOVIO PHARMACEUTICALS's regulatory disclosures and financial reporting.
Inovio Pharmaceuticals reported second-quarter 2026 results with no revenue and a net loss of $6.0 million, or $0.07 per share, compared with a net loss of $23.5 million a year earlier. The narrower loss was largely driven by a $13.9 million non-cash gain from revaluing common stock warrant liabilities, which can cause significant volatility in reported earnings.
Research and development expenses fell to $10.8 million and general and administrative expenses to $7.8 million, bringing total operating expenses to $18.6 million. Cash, cash equivalents and short-term investments were $36.7 million as of June 30, 2026, plus net proceeds of about $18.3 million from a July equity offering, and the company estimates this will fund operations into late first quarter 2027.
Regulatory progress continued for lead candidate INO-3107 for recurrent respiratory papillomatosis, with FDA review of the Biologics License Application underway and a PDUFA target date of October 30, 2026. Inovio is preparing for a potential U.S. launch, having engaged Syneos Health and other commercial partners. Partner ApolloBio reported positive Phase 3 topline results in China for VGX-3100 in cervical dysplasia, and Inovio highlighted promising preclinical data from its DNA-Encoded Monoclonal Antibody and DNA-Encoded Protein platforms.
Inovio Pharmaceuticals reported a net loss of $6.0 million for the quarter and $25.7 million for the first half of 2026, both markedly narrower than the prior-year periods, helped by lower R&D and G&A spending and a $13.9 million non‑cash gain from remeasuring warrant liabilities. Cash and cash equivalents were $31.5 million and short‑term investments $5.1 million at June 30, 2026, with operating cash outflow of $39.6 million in the first half.
The company has an accumulated deficit of $1.84 billion, stockholders’ equity of $4.4 million, and management states there is substantial doubt about its ability to continue as a going concern beyond the first quarter of 2027 without additional capital. Recent equity and warrant offerings in April and July 2026 provided roughly $34.4 million in net proceeds and expanded common shares outstanding to 103.4 million as of August 10, 2026.
Inovio’s lead DNA medicine candidate, INO‑3107 for recurrent respiratory papillomatosis, showed a reduction in surgical interventions in 81.3% of Phase 1/2 trial patients, and the company believes it meets criteria for FDA accelerated approval, though the FDA may disagree, potentially requiring a costly Phase 3 trial. The business remains early‑stage, with no product revenue and significant dependence on regulatory success, external financing, and collaborations.
Adage Capital Management, L.P. and related reporting persons disclose their beneficial ownership in Inovio Pharmaceuticals, Inc. common stock. They report beneficial ownership of 3,428,571 shares of common stock, all issuable upon exercise of warrants held by Adage Capital Partners, L.P. Based on 82,273,237 shares of common stock outstanding as of May 12, 2026, this position represents 4.00% of the class. The reporting persons have shared voting and dispositive power over these shares and no sole voting or dispositive power. The filing states that they own 5 percent or less of the outstanding common stock.
RA Capital Management, L.P., RA Capital Healthcare Fund, L.P., and managers Peter Kolchinsky and Rajeev Shah report beneficial ownership of 10,666,523 shares of Inovio Pharmaceuticals, Inc. common stock, representing 9.99% of the class. The Fund directly holds 7,220,384 shares plus 5,263,157 warrants exercisable for up to 10,526,314 shares. A Beneficial Ownership Blocker in the warrants limits exercises so that aggregate beneficial ownership does not exceed 9.99%, effectively capping current exercisability at 10,666,523 shares. The ownership percentage is based on 82,273,237 shares outstanding as of May 12, 2026 and 21,052,632 shares issued in a July 31, 2026 equity offering.
FMR LLC and Abigail P. Johnson report beneficial ownership of common stock of INOVIO PHARMACEUTICALS INC. FMR LLC reports beneficial ownership of 8,454,797 shares of common stock, representing 10.3% of the class as of June 30, 2026. These shares are reported with sole dispositive power and no shared voting or dispositive power.
Abigail P. Johnson is reported with sole dispositive power over the same 8,454,797 shares and no voting or shared dispositive power, also representing 10.3% of the outstanding common stock. Within this position, Fidelity Small Cap Growth Fund holds 5,632,660 shares, equal to 6.8% of INOVIO’s outstanding common stock as of June 30, 2026. One or more other persons have rights to dividends or sale proceeds for these securities.
Vanguard Capital Management reports a passive ownership stake in Inovio Pharmaceuticals Inc. common stock on Schedule 13G. Vanguard and specified affiliates beneficially own 4,161,566 shares, representing 5.05% of the class.
Vanguard has sole voting power over 511,004 shares and sole dispositive power over all 4,161,566 shares, with no shared voting or dispositive power. The holdings include securities held by various Vanguard funds and managed accounts. No other single person has an interest in more than 5% of these reported securities.
Inovio Pharmaceuticals, Inc. entered into an underwriting agreement with Piper Sandler for a public offering of 21,052,632 shares of common stock and accompanying warrants to purchase up to 42,105,264 shares of common stock, at a combined public offering price of $0.95 per share of common stock and accompanying warrant.
Each warrant is immediately exercisable for two shares at an exercise price of $1.10 per share (or $1.099 per pre-funded warrant) and will expire five years from issuance, subject to beneficial ownership limits of 4.99%, 9.99% or 19.99% as elected by the holder. The underwriter has a 30‑day option to purchase up to 3,157,894 additional shares and/or warrants to purchase up to 6,315,788 shares and has exercised this option with respect to the additional warrants.
Gross proceeds are expected to be approximately $20.0 million before underwriting discounts and commissions and offering expenses, excluding any exercise of the underwriter’s option to purchase additional securities and assuming no exercise of the accompanying warrants. Net proceeds to Inovio are expected to be about $18.3 million after such costs, including the underwriter’s purchase of additional warrants and assuming no exercise of its option to purchase additional shares, with closing expected on or about July 31, 2026, subject to customary conditions.
Inovio Pharmaceuticals, Inc. provides a preliminary estimate of its liquidity, stating that as of June 30, 2026 it had approximately $36.7 million in cash and cash equivalents. This figure is based on management estimates and has not yet gone through full quarter-end closing procedures.
The estimate is described as preliminary unaudited information and may change once financial closing activities and reviews of internal controls are completed. The company notes that its independent registered public accounting firm, Ernst & Young LLP, has not audited, reviewed, examined, or compiled this data, and gives cautionary language about forward-looking statements and potential differences from final results.